KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes.

Sean Wharton, Carel W le Roux, Biykem Bozkurt, Elke Platz, Gabriele Bleckert, Samina Ajaz Hussain, Martina Brueckmann, Elena Startseva, Isabel M Kloer, Lee M Kaplan

Diabetes Obes Metab 28(2) 1490-1498

PMID41216778
PMCIDPMC12803687
DOI10.1111/dom.70263
发表日期2025-11-11
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:FIGURE 1:研究设计图;FIGURE 2:非 KM 图。
摘要

摘要

AIMS: Survodutide is an investigational glucagon receptor/glucagon-like peptide-1 receptor dual agonist that has shown promise for treating obesity and its complications in Phase 2 trials. Two double-blind, randomized, global Phase 3 trials are designed to assess the efficacy and safety of survodutide for treatment of obesity-SYNCHRONIZE™-1 in people with obesity without type 2 diabetes (T2D) and SYNCHRONIZE™-2 in people with obesity and T2D. This paper describes the baseline characteristics of participants in SYNCHRONIZE-2 (ClinicalTrials.gov identifier NCT06066528). MATERIALS AND METHODS: Participants aged ≥18 years with a body mass index (BMI) ≥27 kg/m2 and T2D were randomized 1:1:1 to weekly subcutaneous survodutide (up-titrated to 3.6 or 6.0 mg) or placebo with recommendations for modified diet and physical activity. The primary endpoints are the percentage change in body weight (BW) and achievement of BW reduction of ≥5% from baseline to Week 76. RESULTS: SYNCHRONIZE-2 includes 752 treated participants from 133 sites across 19 countries. At baseline, participants had a mean age of 55.7 years, BMI 36.5 kg/m2, BW 104.1 kg, waist circumference 115.5 cm and haemoglobin A1c 7.4%; 50.7% were female. Overall, 36.2% are from Europe, 32.8% from North America and 22.3% from East Asia. The most common obesity complications included hypertension (69.0%), dyslipidaemia (67.6%), obstructive sleep apnoea (17.3%) and arteriosclerotic cardiovascular disease (10.9%); 78.7% were treated with metformin, 34.2% with sodium-glucose co-transporter-2 inhibitors and 58.6% with lipid-lowering medications. CONCLUSIONS: SYNCHRONIZE-2 will determine the efficacy, safety and tolerability of survodutide for BW reduction in people with obesity and T2D, whose baseline characteristics suggest a representative, diverse cohort.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1Study design of SYNCHRONIZE™‐2. This is a randomized, double‐blind, placebo‐controlled, multinational, Phase 3 clinical trial in people with obesity and type 2 diabetes to evaluate the efficacy, safety and tolerability of survodutide, as an adjunct to a reduced‐calorie diet and increased physical activity for reducing body weight. *The treatment period includes an initial dose‐escalation period that may be extended if one or two re‐escalation attempts are needed due to the occurrence of gastrointestinal symptoms. EOS, end of study; EOT, end of treatment. Adapted from fig. 1 in Wharton et al., 19 used under CC BY‐NC 4.0.
非 KM Figure
FIGURE 2Complications of obesity in the overall trial cohort at baseline. AFib, atrial fibrillation; ASCVD, arteriosclerotic cardiovascular disease (defined as coronary artery disease, myocardial infarction, stroke or peripheral artery disease); CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DLD, dyslipidaemia; HTN, hypertension; MASH, metabolic dysfunction‐associated steatohepatitis; OSA, obstructive sleep apnoea.
非 KM Figure